Nakajima Kenichi, Edenbrandt Lars, Mizokami Atsushi
Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan.
Department of Clinical Physiology and Nuclear Medicine, University of Gothenburg, Gothenburg, Sweden.
Int J Urol. 2017 Sep;24(9):668-673. doi: 10.1111/iju.13386. Epub 2017 May 26.
Bone scintigraphy is one of the first-line imaging modalities for the screening and follow up of bone metastasis in patients with prostate cancer. The amount (%) of bone metastasis can be calculated using a bone scan index thanks to recent advances in quantitative bone scintigraphy. Since an artificial neural network was applied for hot-spot characterization and quantitation, the bone scan index has become a simple, reproducible and practical means of quantifying bone metastasis. The bone scan index is presently considered as an imaging biomarker of bone metastasis. The present article summarizes the principles and application of bone scan index using dedicated software (EXINI bone in Europe and North America; BONENAVI in Japan), and the advantages and cautions of using the bone scan index. The bone scan index could serve as a practical marker with which to monitor disease progression and treatment effects in multicenter studies, and to manage prostate and other types of cancer in the clinical setting.
骨闪烁扫描术是前列腺癌患者骨转移筛查及随访的一线成像方式之一。由于定量骨闪烁扫描术的最新进展，可使用骨扫描指数计算骨转移的数量（%）。自从将人工神经网络应用于热点特征描述和定量分析以来，骨扫描指数已成为一种简单、可重复且实用的骨转移定量方法。目前，骨扫描指数被视为骨转移的一种成像生物标志物。本文总结了使用专用软件（欧洲和北美的EXINI bone；日本的BONENAVI）计算骨扫描指数的原理及应用，以及使用骨扫描指数的优势和注意事项。骨扫描指数可作为一种实用指标，用于在多中心研究中监测疾病进展和治疗效果，并在临床环境中管理前列腺癌及其他类型的癌症。
